Practice · Vascular Surgery

Endovascular pipeline, engineered around your OR calendar.

We build referrer-network demand across AAA/EVAR, peripheral arterial disease, varicose vein and dialysis access programmes — routed via nephrologists, diabetologists and cardiologists, not consumer ads.

For Chiefs of Vascular Surgery, Endovascular Program Heads and MDs of cardio-vascular super-specialties.

Request a Vascular Pipeline Blueprint →Review case evidence

EVAR Volume

+186%

12-month cohort

AV Fistula Cases

+240%

nephrology network activation

Endo Case Mix

72%

vs. open surgery, post-engagement

OT Utilization

81%

vascular hybrid room

Procedure-level demand engineering

We target the procedures that move your P&L, not the ones that fill the OPD queue.

CATCHMENT TIER · PRICE RESTATEMENT

ARPU differs materially between Metro, Tier-2 and Tier-3 catchments. Switch tier to restate every procedure band against the payer mix and package ceilings we observe in that market — not a single all-India number.

Viewing Metro / Tier-1 · Representative catchments: Delhi NCR, Mumbai, Bengaluru, Chennai, Hyderabad, Kolkata, Pune.

EVAR / Open AAA Repair

₹6.5 L–14 L

Screening & second-opinion funnel

PAD Endovascular

₹2.4 L–5.5 L

Diabetologist-referred claudication

Carotid Endarterectomy / CAS

₹3.2 L–6.5 L

TIA & stroke-workup pathway

Varicose Vein (RFA/EVLT)

₹90K–2.2 L

Cosmetic + venous-ulcer dual funnel

AV Fistula / Dialysis Access

₹80K–1.8 L

Nephrology-network referral

DVT & Thromboembolectomy

₹1.4 L–3.2 L

ED & inpatient rapid-intake

Methodology. Base bands reflect RDV's engagement dataset across 47 super-specialty hospitals, reconciled against CGHS/ECHS package rates, state-scheme ceilings (Ayushman Bharat PM-JAY, CMCHIS, YSR Aarogyasri) and empanelled TPA grids. Tier multipliers applied: Metro 1.00× · Tier-2 0.72× · Tier-3 0.55×. Actuals swing with payer mix, consultant-fee split and implant/consumable choice — the written Blueprint restates every band against your own HIS billing history before any spend is committed.

Clinical referral pathway

Intent → triage → consult → admission. Instrumented at every gate.

01 · Intent capture
Symptom, condition and referrer-based intent capture across catchment.
02 · Clinical triage
Specialty-trained nurse/coordinator triage with report upload before consult.
03 · Consultant handoff
Calendar-synced booking to the operating consultant with pre-read notes.
04 · Admission & OT slotting
CRM ↔ HIS tag: admission source, procedure code, OT date.

Case snapshot

2.4× endovascular volume, +240% AV fistula referrals.

A representative RDV engagement in the Vascular Surgery practice line. Individual results vary by catchment, clinical capacity and payer mix.

Setting: Vascular unit inside cardiac super-specialty, 60 beds
Duration: 10 months
Cohort: n = 780 referrer-network enquiries
Outcome: 2.4× endovascular volume, +240% AV fistula referrals

Figures engagement-verified against hospital HIS. No outcome guarantees implied; per NMC advertising guidelines.

Why Chiefs of Vascular choose RDV

Trust is earned in the operating logic, not the pitch deck.

Referrer-network primacy

Vascular growth is 80% referrer network, 20% consumer. We build the nephrology and diabetology MOUs first.

Hybrid-room capacity governance

Intake throttled to hybrid-room availability — no queue overflow, no downstream complications.

Screening-programme rigour

AAA screening framed clinically, never fear-marketed. Every claim internally audited.

Dialysis-access continuity

AV fistula patients enter a documented surveillance pathway, generating multi-year retention revenue.

From an engagement

"The nephrology MOU programme rebuilt our access practice from scratch. It felt like a professional partnership, not a marketing engagement."

— Chief of Vascular Surgery · 60-bed cardio-vascular unit

Attribution anonymised per client confidentiality; engagement code verifiable in the founder-led review.

Talk directly to the founding partner who ran this engagement.

Request a Vascular Blueprint →

48-hour founder-led review. Fixed-scope. No lock-in.

Clinical authority

Content your clinicians will co-sign.

Vascular surgeon PAD staging decision framework
Hybrid-room capability disclosure page
Nephrology co-management protocol library

Compliance posture

Every asset, every claim, medically reviewed.

NMC norms — no comparative device or stent-brand claims
DCGI-safe messaging on endovascular devices
Screening-programme claims backed by internal audit

Catchment note: Nephrology and diabetology network engineering across metros; AAA screening corridors in senior-heavy catchments.

The 21-day diagnostic

What the fixed-scope engagement actually contains — for Vascular.

No mystery, no scope creep. Each week is instrumented and delivered against a checklist your MD and Chief signs.

Week 1
Vascular OT & hybrid-room utilisation audit.
Week 2
Nephrology, diabetology and cardiology referrer mapping.
Week 3
Procedure-mix unit economics and screening-programme ROI model.
Week 4
Founder-led blueprint with Chief of Vascular.

Where we compound

The unfair edge — for Vascular specifically.

Nephrology & diabetology MOU network operational at scale
AAA screening framework compliant with NMC + evidence-graded
Endovascular-first messaging that respects open-surgery indication

Practice guarantees

What we commit to in writing.

Fixed-scope diagnostic — no retainer, no annual lock-in
HIS-verified attribution — every claimed admission traceable to source
No media markup — you see raw platform invoices at cost
Founder-led — the partner who scopes the engagement does the work

Objections we hear

The three questions MDs ask before signing.

We keep our answers on the record. If yours isn't here, ask it in the qualification form — the founding partner replies personally within 48 hours.

Vascular can't be consumer-marketed.

Correct — and we don't try. This is a referrer-network engagement first, screening-programme second, consumer-media distant third.

Our hybrid room is already at capacity.

Then intake is throttled to capacity. We'd rather grow slower than compromise downstream outcomes.

Varicose vein is a cosmetic distraction.

It's also a venous-ulcer funnel that generates dialysis-access-adjacent revenue. We segment both intents; you decide the mix.

FAQ

The questions Chiefs of Vascular ask us first.

If yours isn't here, put it in the qualification form — our founding partner will answer it in the 48-hour review.

How do you build nephrology MOUs at scale?+

One district at a time, with a documented value exchange: joint access surveillance, co-authored patient education and shared outcome tracking.

Can varicose vein be marketed compliantly?+

Yes — through venous-disease education, symptom-based intent and clinical-benefit framing. Never through cosmetic before-and-afters.

What about AAA screening ethics?+

Screening is offered to guideline-defined risk cohorts (age, smoking history, family history), never population-broadcast. We codify criteria before campaign launch.

Next step